Viatris Inc.(VTRS) Stock Research - Grey Stern Research

Viatris Inc. (VTRS) Stock Analysis

$13.20 (0.84%)

VTRS Financial Performance


Use the table below to view Viatris Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $13.20 -
52 Week Low $9.31 -
52 Week High $13.62 -
Market Cap $15.8 Billion 4/11
Gross Margin 39% 8/11
Profit Margin 3% 7/11
EBITDA margin 6% 8/11
Q3 - 2024 Revenue $3.7 Billion 3/11
Q3 - 2024 Earnings $94.8 Million 7/11
Q3 - 2024 Free Cash Flow $750.5 Million 3/11
Trailing 4 Quarters Revenue $15.0 Billion 3/11
Trailing 4 Quarters Earnings -$883.3 Million 9/11
Quarterly Earnings Growth -71% 10/11
Annual Earnings Growth -179% 11/11
Quarterly Revenue Growth -5% 11/11
Annual Revenue Growth -4% 8/11
Cash On Hand $1.9 Billion 3/11
Short Term Debt $1.4 Billion 3/11
Long Term Debt $16.2 Billion 4/11

Viatris Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Viatris Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 7/11
PS 1.05 9/11
PB 0.80 9/11
PC 8.39 5/11
Liabilities to Equity 1.26 5/11
ROA -0.02 7/11
ROE -0.04 6/11
Current Ratio 1.79 6/11
Quick Ratio 0.08 8/11
Long Term Debt to Equity 0.82 4/11
Debt to Equity 0.89 4/11
Burn Rate 2.06 4/11
Cash to Cap 0.12 7/11
CCR 7.92 1/11
EV to EBITDA 139.42 3/11
EV to Revenue 2.10 8/11

Company Details

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

CEO: Mr. Robert J. Coury

Website: https://www.viatris.com

Address: 1000 Mylan Boulevard Canonsburg, PA

Exchange: NASDAQ Global Select

Industry: Drug Manufacturers—Specialty & Generic

Viatris Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Viatris Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Teva Pharmaceutical Industries Limited TEVA $18.9 Billion
Zoetis Inc. ZTS $79.8 Billion
Lantheus Holdings, Inc. LNTH $6.2 Billion
Catalent, Inc. CTLT $11.2 Billion
Dr. Reddy's Laboratories Limited RDY $11.9 Billion
Emergent BioSolutions Inc. EBS $533.2 Million
Bausch Health Companies Inc. BHC $2.9 Billion
Elanco Animal Health Incorporated ELAN $6.7 Billion
Takeda Pharmaceutical Company Limited TAK $43.9 Billion
Tilray Brands, Inc. TLRY $1.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
VTRS Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 3.7 Billion $94.8 Million
Q2 2024 $ 3.8 Billion -$326.4 Million
Q1 2024 $ 3.7 Billion $113.9 Million
Q4 2023 $ 3.8 Billion -$765.6 Million
Q3 2023 $ 3.9 Billion $331.6 Million
Q2 2023 $ 3.9 Billion $264.0 Million
Q1 2023 $ 3.7 Billion $224.7 Million
Q4 2022 $ 3.9 Billion $1.0 Billion

View All

VTRS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $1.9 Billion $44.8 Billion $17.6 Billion $19.8 Billion
Q2 2024 $918.5 Million $45.3 Billion $17.4 Billion $19.5 Billion
Q1 2024 $1.0 Billion $47.3 Billion $18.2 Billion $20.0 Billion
Q4 2023 $991.9 Million $47.7 Billion $18.1 Billion $20.5 Billion
Q3 2023 $1.3 Billion $48.7 Billion $18.4 Billion $20.9 Billion
Q2 2023 $629.2 Million $48.7 Billion $18.6 Billion $20.8 Billion
Q1 2023 $506.6 Million $49.3 Billion $18.6 Billion $20.9 Billion
Q4 2022 $1.3 Billion $50.0 Billion $19.3 Billion $21.1 Billion

View All

VTRS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $750.5 Million -$76.0 Million $961.6 Million
Q2 2024 $309.6 Million -$69.5 Million -$97.4 Million
Q1 2024 $563.8 Million -$50.8 Million $22.3 Million
Q4 2023 $644.9 Million $165.5 Million $644.9 Million
Q3 2023 $930.0 Million $95.9 Million $930.0 Million
Q2 2023 $425.9 Million -$89.0 Million $120.7 Million
Q1 2023 $888.7 Million -$82.5 Million -$751.8 Million
Q4 2022 -$23.3 Million -$165.9 Million $612.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions